Vericel to Present at Multiple Upcoming Investor ConferencesCAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences:
Vericel Reports Fourth Quarter and Full-Year 2024 Financial ResultsFull-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22%
Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2024 financial results on Thursday, February 27, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025.
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2024 financial results on Thursday, November 7, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at 1:05 p.m. ET on Friday, September 6, 2024.
Vericel Announces FDA Approval and Commercial Availability of MACI ArthroFirst Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m. ET on Wednesday, August 14, 2024.
Vericel Reports Second Quarter 2024 Financial ResultsTotal Revenue of $52.7 Million, with MACI Revenue Growth of 21% to $44.1 Million
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources OfficerCAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel’s Head of Human Resources since September 2010.
Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2024 financial results on Thursday, August 1, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024.
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
5 medical stocks growing earnings by triple digitsThere is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (
NASDAQVCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 11:00 a.m. ET (8:00 a.m. PT) on Monday, February 12, 2024.
Vericel Corp. (NASDAQ: VCEL) Sets New 52-Week High in Tuesday SessionShares of Vericel Corporation (
NASDAQVCEL) traded at a new 52-week high today and are currently trading at $34.41. So far today, approximately 207.57k shares have been exchanged, as compared to an average 30-day volume of 302.63k shares.
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial ResultsFull-Year Total Revenue Expected to be Approximately $197.5 Million, Representing 20% Growth, with Fourth Quarter Revenue Growth of 23% to $65 Million
